News
Report provides key statistics on employers’ liability, public liability, and commercial property insurance in Ireland; including data on claims costs and settlement channels. On average, employers’ liability and public liability claims settled through litigation cost more and take longer to settle than claims settled directly or via the PIAB. Insurers’ income and expenditure on Employers’ […]
The adoption of sanctions places legally binding obligations on all individuals and entities The Central Bank is sharing information with business representatives regarding individual and firm-level obligations Sanctions breaches must be reported to An Garda Siochana Against the backdrop of Russia’s invasion of Ukraine and the introduction of EU Regulations relating to financial sanctions, the […]
IBAN discrimination is an issue across Europe as more firms offer financial services cross border The Central Bank has contacted regulated firms and business representative bodies in Ireland to reinforce all organisations’ responsibilities under SEPA Supporting consumer choice to choose a provider with a non-Irish IBAN is important as Ulster Bank and KBC exit the […]
Insuring for our Future Good afternoon, it is a pleasure to address you today.1 A well-functioning insurance market provides important benefits and supports for society as a whole. Insurance protects people from financial loss, should unforeseen events arise. At a macro level you have an important role in channelling savings into financial markets and ultimately […]
Thank you for joining us today for the release of the first FSR of 2022. It gives me particular pleasure to welcome some of you in person for today’s event after more than two years, our first hybrid version of the release of the Review. We are meeting today at a time when a series […]
Sarepta Therapeutics Inc. SRPT, +5.14% shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration. Sarepta disclosed that a patient in a study of a proposed drug for Duchenne muscular dystrophy suffered a “serious adverse event of […]